Date | Price Target | Rating | Analyst |
---|---|---|---|
7/26/2024 | $58.00 | Outperform | Robert W. Baird |
6/27/2024 | Overweight | Cantor Fitzgerald | |
5/16/2024 | $40.00 | Buy | H.C. Wainwright |
2/15/2024 | $44.00 | Buy | Stifel |
12/26/2023 | $22.00 | Buy | Jefferies |
11/22/2023 | $23.00 | Outperform | Wedbush |
10/30/2023 | $45.00 | Buy | Guggenheim |
9/28/2023 | $24.00 | Outperform | Raymond James |
Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating.
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September: Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York CityCantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York CityStifel 2024 Virtual Immunology and Inflammation Sum
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24 Approximately $361 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the se
NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Mult
S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
424B3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00
Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with a rating of Overweight
H.C. Wainwright initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $40.00
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)